Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
Surgery Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland.
Ann Surg Oncol. 2023 May;30(5):2716-2725. doi: 10.1245/s10434-022-13052-4. Epub 2023 Jan 17.
BACKGROUND: The age-specific risks of mortality for patients with esophagogastric cancer and their probability of surgical treatment are not well-known. METHODS: This population-based, nationwide cohort study included all patients with esophageal or gastric (esophagogastric) cancer in Sweden between 1990 and 2013, with follow-up evaluation throughout 2018. Age at diagnosis (exposure) was categorized into nine 5-year groups. The main outcome was 5-year all-cause mortality. The secondary outcomes were 90-day all-cause mortality, 5-year disease-specific mortality, 5-year disease-specific mortality excluding 90-day all-cause mortality, and non-operation. For mortality outcomes, Cox regression provided hazard ratios (HRs) with 95% confidence intervals (95% CIs) adjusted for confounders. For non-operation, logistic regression provided odds ratios (ORs) with 95% CIs. RESULTS: Among 28,725 patients, 11,207 (39.0%) underwent surgery. For those who underwent surgery, the HRs of 5-year all-cause mortality were stable before the ages of 65 to 69 years. After that, it gradually increased for patients 65 to 69 years old (HR, 1.13; 95% CI, 1.01-1.26), patients 75 to 79 years old (HR, 1.29; 95% CI, 1.56-1.44), and patients older than 85 years (HR, 1.84; 95% CI, 1.60-2.11) compared with those younger than 50 years. Analyses of age as a continuous variable, other mortality outcomes and stratification by comorbidity and tumor type showed similar results. The odds of non-operation increased for patients 75 to 79 years old (OR, 2.09 [95% CI, 1.84-2.94] for patients 80 to 84 years old and OR, 5.00 [95% CI, 4.31-5.78] for patients ≥85 years old or older), compared with those younger than 50 years. CONCLUSION: Older age, starting from 65 years, is associated with worse survival after surgery for esophagogastric cancer, and from 75 years with lower odds of surgical treatment.
背景:特定年龄段的食管胃癌症患者的死亡率及其手术治疗的可能性尚不清楚。
方法:这是一项基于人群的全国性队列研究,纳入了 1990 年至 2013 年间在瑞典患有食管或胃(食管胃)癌的所有患者,并在 2018 年进行了随访评估。诊断时的年龄(暴露)分为九个 5 年组。主要结局为 5 年全因死亡率。次要结局为 90 天全因死亡率、5 年疾病特异性死亡率、排除 90 天全因死亡率的 5 年疾病特异性死亡率和非手术治疗。对于死亡率结局,Cox 回归提供了调整混杂因素后的风险比(HR)和 95%置信区间(95%CI)。对于非手术治疗,Logistic 回归提供了 95%CI 的比值比(OR)。
结果:在 28725 名患者中,有 11207 名(39.0%)接受了手术。对于接受手术的患者,5 年全因死亡率的 HR 在 65 至 69 岁之前保持稳定。此后,65 至 69 岁的患者(HR,1.13;95%CI,1.01-1.26)、75 至 79 岁的患者(HR,1.29;95%CI,1.56-1.44)和 85 岁以上的患者(HR,1.84;95%CI,1.60-2.11)的 HR 逐渐升高,与 50 岁以下的患者相比。年龄作为连续变量的分析、其他死亡率结局以及按合并症和肿瘤类型进行的分层分析显示出相似的结果。与 50 岁以下的患者相比,75 岁至 79 岁的患者(OR,2.09 [95%CI,1.84-2.94])和 80 岁至 84 岁的患者(OR,5.00 [95%CI,4.31-5.78])的非手术治疗几率增加。
结论:年龄较大,从 65 岁开始,与食管胃癌症手术后的生存状况较差相关,从 75 岁开始,手术治疗的可能性较低。
Ann Surg Oncol. 2023-5
Eur J Surg Oncol. 2016-8
Ann Surg Oncol. 2021-1
J Natl Cancer Inst. 2015-3-5
BMC Gastroenterol. 2025-4-8
JAMA Netw Open. 2024-10-1
Lancet. 2020-8-29
Ann Surg Oncol. 2021-1
Ann Surg Oncol. 2018-7-9
J Gastrointest Surg. 2018-2-5
Eur J Epidemiol. 2017-9
World J Gastrointest Oncol. 2017-6-15